A New Canadian Company is Detecting Cancer Earlier Than Ever Before

VANCOUVER, British Columbia-- ​​To most people, liquid biopsy is a new technology - using a simple blood sample to check for cancer cells in the body, instead of an invasive and expensive tumor biopsy. However, a Canada-based precision oncology company, CTOAM (Cancer Treatment Options and Management Inc.), has been using liquid biopsies with cancer patients for over four years. And now, after significant investment in research and development, CTOAM is launching a new biotech company: Liquid Biopsy Labs (LBL). LBL provides cancer patients and clinics with access to a new patent-pending technology that produces more accurate results than any other commercial liquid biopsy test on the market. Standard liquid biopsies measure DNA from blood, but they do not identify the source of this DNA: It may be from dead cancer cells (due to treatment); live cancer cells traveling via blood (metastasis); normal cells; or extracellular vesicles such as exosomes. In other words, standard liquid biopsies cannot tell if a treatment is working because the source of the DNA is not specified by the test.